Project Grant R21NS135773
Award Date
9/15/23
Completion Date
8/31/25
Dollars Obligated
$429K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $438,365 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the role of the CD38 protein and its potential as a therapeutic target for Spinal and Bulbar Muscular Atrophy (SBMA). The research aims to use stem cell technology and CRISPR-corrected isogenic controls to examine metabolic alterations in SBMA patient-derived...
This Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the role of somatic CAG repeat instability in the pathogenesis of Spinal and Bulbar Muscular Atrophy (SBMA). The $429,000 award to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, will evaluate the tissue selectivity and...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $151,600 project grant under CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders to the Philadelphia College of Osteopathic Medicine (PCOM) to generate and characterize a Cre-Lox regulated transgenic zebrafish model of spinal and bulbar muscular atrophy (SBMA). This rare neuromuscular disorder, also known as Kennedy's Disease, affects men and currently has no cure or therapy....
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $676,789 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program to the Buck Institute for Research on Aging. The grant supports research to investigate the in vivo impact of N6-methyladenosine (m6A), a common mRNA modification, on synaptic function and neurotransmitter release. The research aims to establish critical roles for the epitranscriptome in...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on developing a novel drug candidate to treat demyelinating neuropathies. The $352,073 award will support rigorous in vivo testing of the experimental ABCA1 agonist drug, CS6253, in validated mouse models of hereditary peripheral nerve disorders characterized by impaired...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $195,000 to support research on understanding the mechanism of action of small molecule splicing modulators for the potential treatment of Huntington's disease. The research aims to use a combination of cryo-EM structural determination and biochemical approaches to evaluate the...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to investigate the role of proton-mediated signaling at the neuromuscular junction in amyotrophic lateral sclerosis (ALS) models. The $387,525 award to the Board of Regents of the Nevada System of Higher Education, operating through the University of Nevada, Reno, will...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $226,500 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of Georgia Research Foundation, Inc. to characterize and treat peripheral nervous system dysfunction in Sanfilippo syndrome (mucopolysaccharidosis type IIIA). The project aims to develop novel cellular disease models using patient-derived induced pluripotent stem cells to...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $395,009 to the University of California, Davis to lay the foundation for developing a molecular therapy for ADNP syndrome. The key products and services to be delivered under this 2-year award include: Testing the presumed mechanism of action of antisense oligonucleotides (ASOs) that can...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $645,391 to The Trustees of Columbia University in the City of New York to conduct research on the effects of re-expressing embryonic motor neuron selector transcription factors in mouse models of amyotrophic lateral sclerosis (ALS) and in ALS motor neurons derived from induced...